Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $50.00 at Citigroup

Key Points

• Citigroup raised the price target for Kiniksa Pharmaceuticals International from $45.00 to $50.00, indicating a potential upside of 31.86% based on the current stock price.
• Analysts maintain a consensus rating of "Moderate Buy" for Kiniksa Pharmaceuticals, with a broader outlook including other recent analysts boosting their target prices as well.
• Despite positive earnings exceeding estimates, Kiniksa's stock has recently seen insider selling, with significant transactions reported in September.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) had its price target raised by analysts at Citigroup from $45.00 to $50.00 in a report released on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. Citigroup's price objective suggests a potential upside of 31.86% from the company's current price.

Several other equities analysts also recently commented on KNSA. Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an "overweight" rating in a report on Thursday, September 25th. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a report on Monday, October 6th. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the stock an "outperform" rating in a report on Monday. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $46.86.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA traded down $1.00 during mid-day trading on Friday, reaching $37.92. The stock had a trading volume of 106,006 shares, compared to its average volume of 631,065. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of 948.49 and a beta of 0.16. Kiniksa Pharmaceuticals International has a 12 month low of $17.82 and a 12 month high of $39.43. The business has a fifty day moving average of $35.72 and a 200 day moving average of $29.60.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, research analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, insider Ross Moat sold 3,523 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $35.31, for a total transaction of $124,397.13. Following the sale, the insider owned 9,415 shares of the company's stock, valued at $332,443.65. This represents a 27.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Michael R. Megna sold 11,000 shares of the company's stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $34.84, for a total transaction of $383,240.00. Following the sale, the chief accounting officer directly owned 38,011 shares in the company, valued at approximately $1,324,303.24. The trade was a 22.44% decrease in their position. The disclosure for this sale can be found here. Insiders sold 596,839 shares of company stock worth $20,357,964 in the last ninety days. Company insiders own 53.48% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently made changes to their positions in KNSA. GAMMA Investing LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $301,000. Asset Management One Co. Ltd. purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $41,000. Wealthquest Corp purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $42,000. Finally, AMI Asset Management Corp raised its stake in shares of Kiniksa Pharmaceuticals International by 50.3% in the first quarter. AMI Asset Management Corp now owns 77,688 shares of the company's stock valued at $1,725,000 after acquiring an additional 26,010 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.